Delcath Systems (DCTH) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Press Release: Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call
Dow JonesFeb 20 08:32 ET
Here's What Could Help Delcath Systems (DCTH) Maintain Its Recent Price Strength
Zacks Feb 17 08:00 ET
Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma
BusinesswireFeb 14 08:30 ET
Home Healthcare Inflation Is Stubbornly High -- WSJ
WSJFeb 12 12:30 ET
Buy Rating on Delcath Systems: Unique Market Position and Growth Potential
TipRanksFeb 10 06:55 ET · Ratings
Wall Street Analysts Think Delcath Systems (DCTH) Could Surge 33.74%: Read This Before Placing a Bet
Zacks Feb 6 09:00 ET

Comments

Teddy123

Feb 14 08:10

Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma

$Delcath Systems (DCTH.US)$
Major Treatment Breakthrough: NCCN Widens Access to Revolutionary Melanoma Therapy

bro why so serious

Nov 14, 2024 06:20

$Delcath Systems (DCTH.US)$ why always fall

Jaguar8

Aug 27, 2024 07:31

NEWS

$Delcath Systems (DCTH.US)$
Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients
Delcath Systems, Inc. (Nasdaq: DCTH) announced positive outcomes from an independent study on hepatic perfusion for uveal melanoma patients. The study, conducted by researchers at Moffitt Cancer Center, compared Delcath's HEPZATO KIT™ to immunotherapy and other liver-directed therapies. Key findings include:
1. Overall Survival (OS): Median OS ...

Trytosaveabit

Aug 26, 2024 15:03

Update

$Delcath Systems (DCTH.US)$ Reuters· 1 min ago1min
Delcath Systems, Inc. Announces Promising Results From Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors

1

Jaguar8

Aug 26, 2024 15:01

NEWS

$Delcath Systems (DCTH.US)$
Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors
Delcath Systems (Nasdaq: DCTH) announced promising results from an independent study on its CHEMOSAT® Hepatic Delivery System for liver tumors. The study, conducted at the University Hospital of Leipzig, Germany, evaluated 33 patients with various cancers, including uveal melanoma and cholangiocarcinoma. Key findings include:
- A 91% diseas...

DCTH Delcath Systems

Trade Overview

Capital Trend

News

Comments

Trending Stocks